What ChondroFiller is actually designed to repair

The design logic of ChondroFiller™ (branded here as Liquid Cartilage™) makes the candidacy limits almost self-evident once you understand it.

ChondroFiller is an acellular collagen scaffold — it contains no donor cells of its own. Delivered as a liquid under ultrasound guidance directly into the hip joint, it gels in situ and creates a temporary matrix at the defect site. The scaffold then recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, supporting endogenous repair through a process known as acellular matrix-induced chondrogenesis. It does not regrow cartilage by itself; it provides the structural environment for the body's own repair processes to do that work.

Two structural requirements follow directly from this mechanism. First, the defect must be focal and contained — typically an isolated Grade III or IV lesion up to 6 cm² in area. Precise ultrasound-guided placement cannot compensate for damage that is too diffuse or widespread. Second, the tissue immediately surrounding the defect must be structurally intact: the scaffold depends on healthy cartilage borders to anchor and protect it during the six-to-twenty-four-month repair window.

Those two requirements — focal damage and a sound biological neighbourhood — define the outer boundary of suitability before any patient-specific factors are considered.

Advanced hip osteoarthritis: the single biggest exclusion

The clearest signal of non-candidacy comes not from consensus documents but from the only published hip-specific cohort study of ChondroFiller to date. Mazek (2021) followed 26 adults who underwent hip arthroscopy with ChondroFiller for acetabular cartilage lesions greater than 2 cm², all with co-existing femoroacetabular impingement. The study's own conclusion is unambiguous: patients with pre-existing osteoarthritis at Tönnis grade 2 or 3 had poor results. Two from that group subsequently required total hip replacement.

The cohort is small, and that limitation deserves honest acknowledgement — 26 patients is a narrow evidence base from which to draw firm thresholds. Yet the finding rests on sound biological reasoning rather than an arbitrary grading rule. In a hip joint with advanced osteoarthritis, the surrounding cartilage borders — the structural anchor on which the scaffold depends — are themselves degraded or absent. The joint environment is also chronically pro-inflammatory, which undermines the endogenous repair process that acellular matrix-induced chondrogenesis relies upon. The scaffold requires a functional biological neighbourhood; advanced OA removes it. That explanation is consistent with the clinical picture described across multiple sources beyond the Mazek paper.

In the broader injectable scaffold literature, Kellgren-Lawrence grade IV on plain X-ray represents the comparable threshold — bone-on-bone wear indicating the diffuse, generalised damage that lies outside ChondroFiller's focal-repair premise.

A practical implication is that pain intensity alone cannot determine suitability. Two patients presenting with near-identical hip discomfort may have strikingly different findings on MRI — one showing a contained focal lesion in an otherwise sound joint, the other showing widespread cartilage loss across the weight-bearing surfaces. Symptom scores are not a substitute for structural imaging; MRI confirmation of the defect pattern and its surrounding tissue quality is a prerequisite before any candidacy decision can be reached.

Hip-specific structural conditions that fall outside focal repair

Ball-and-socket geometry defines the hip in ways that distinguish it from other joints — and those same anatomical features create a category of structural conditions where focal cartilage repair is simply the wrong treatment, regardless of defect grade.

Avascular necrosis of the femoral head collapses the distinction between bone and cartilage disease. AVN involves segmental death of the bony femoral head itself; the overlying cartilage damage is a downstream consequence of failed bone perfusion, not a primary cartilage lesion. Placing a collagen scaffold over a defect whose underlying bone architecture is dying or has already partially collapsed cannot produce durable repair — the biological support structure the scaffold depends upon is not present.

Developmental dysplasia of the hip presents a different problem: altered joint geometry. DDH changes the orientation and coverage of the acetabulum, creating mechanical loading patterns across the joint surface that a cartilage scaffold is not designed to correct. Injecting ChondroFiller into a dysplastic hip does not restore the socket geometry driving the abnormal load distribution.

Bipolar or 'kissing' lesions — where cartilage damage exists simultaneously on the femoral head and the opposing acetabular surface — exceed the focal-repair premise in a specific way. The scaffold placed on one surface will make direct contact with a damaged opposing surface during every loading cycle, undermining the protected healing environment the repair process requires.

FAI (femoroacetabular impingement) is not itself a disqualifying factor. The Mazek (2021) cohort specifically treated acetabular lesions in patients with co-existing FAI, with good or excellent results in the majority at three to five years. The important distinction is whether the bony cam or pincer deformity driving impingement has been addressed. Untreated bony impingement continues to damage cartilage mechanically — repairing the lesion without resolving its cause risks early failure. A specialist imaging review, typically MRI and sometimes CT to assess bony anatomy, is therefore essential before candidacy for any focal repair can be confirmed.

Mechanical and joint-space prerequisites the hip must meet

Even when a hip cartilage defect is focal and the surrounding joint appears broadly healthy, the procedure itself imposes structural demands that the hip must meet independently of any disease-state diagnosis.

Ultrasound-guided placement of the collagen scaffold requires sufficient residual joint space for safe, accurate needle positioning. Severe joint-space narrowing — the kind seen in advanced osteoarthritis — can make image-guided delivery unreliable, irrespective of whatever grade is recorded on MRI or plain X-ray. Where the hip simply cannot accommodate instrumentation safely, the procedure is not viable.

Joint stability and alignment matter for a different reason: the scaffold needs mechanical protection across a 6–24-month healing window while the patient's own cells colonise and mature within it. Significant instability or uncorrected malalignment generates ongoing shear forces across the repair site with each loading cycle. That mechanical disruption during healing can undermine scaffold integration even where the initial placement is technically successful.

Conservative treatment — physiotherapy, anti-inflammatory medication, and earlier injection therapy — should have been trialled and documented before ChondroFiller is considered. This is not a bureaucratic staging requirement; it is sound clinical sequencing that confirms the defect is genuinely refractory and that simpler measures have been given a fair opportunity.

Active infection in or around the hip joint is an absolute contraindication. Introducing a CE-marked Class III biologic implant into an infected environment carries serious clinical risk, and no element of the candidacy picture alters that position.

Absolute contraindications independent of hip disease stage

Four contraindications sit outside the OA-grading and structural taxonomy covered above — they apply regardless of how focal or technically suitable a cartilage defect might appear on imaging.

Confirmed collagen allergy. ChondroFiller is composed of murine-derived Type I collagen. A documented sensitivity to collagen products rules the scaffold out entirely; there is no alternative formulation to substitute.

Inflammatory arthropathy. Rheumatoid arthritis, psoriatic arthritis, and related systemic conditions are contraindicated because the exclusion is not about the cartilage appearance — it is about the joint environment. Active immune-mediated inflammation disrupts scaffold integration and undermines the endogenous repair process the scaffold depends upon. These patients require a disease-modifying treatment pathway, not a local scaffold.

Pregnancy. No safety data exist for injectable biologic therapies of this class during pregnancy; ChondroFiller is not used in this setting.

Tumours near the hip joint. Any neoplastic process at or adjacent to the joint makes local injection inadvisable.

These are clinical safety criteria that a thorough pre-procedure assessment will check systematically — not conditions patients need to self-identify before seeking advice.

What to do if ChondroFiller is not right for your hip

Not qualifying for ChondroFiller narrows the field without closing it. The question shifts from which repair scaffold to which pathway fits the diagnosis — and that shift requires accurate structural information, not a symptom report alone.

For patients excluded due to advanced hip osteoarthritis, Arthrosamid — a different mechanism addressed in an earlier section — remains a relevant option for symptomatic relief in a worn joint. Those with structural diagnoses such as AVN or developmental dysplasia will be directed toward specialist pathways appropriate to those conditions, rather than into a repair-scaffold discussion.

The lincolnshirehip.com/chondrofiller-suitability self-assessment, six questions reviewed by Professor Paul Lee, offers a structured way to frame a first consultation before attending in person; patients outside ChondroFiller candidacy are signposted toward relevant alternatives rather than left without direction. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for hip assessment at Sleaford and Grantham.

The diagnosis determines the direction. Whether the outcome is scaffold treatment, a different injection, or a specialist structural pathway, the same principle holds: an accurate picture of what is happening inside the hip is what makes a treatment plan coherent rather than speculative.